BPG is committed to discovery and dissemination of knowledge
Articles in Press
11/6/2019 7:41:05 PM | Browse: 439 | Download: 330
Publication Name World Journal of Clinical Oncology
Manuscript ID 47669
Country Uruguay
Category Oncology
Manuscript Type Systematic Reviews
Article Title Current concepts in ameloblastoma-targeted therapies in B-raf proto-oncogene serine/threonine kinase V600E mutation: Systematic review
Manuscript Source Invited Manuscript
All Author List Rogelio González-González, Sandra López-Verdín, Jesús Lavalle-Carrasco, Nelly Molina-Frechero, Mario Isiordia-Espinoza, Ramón G Carreón-Burciaga and Ronell Bologna-Molina
Funding Agency and Grant Number
Corresponding Author Ronell Bologna-Molina, DDS, MSc, PhD, Postdoc, Professor, Research Scientist, Senior Scientist, Molecular Pathology, School of Dentistry, Universidad de la República de Uruguay (UDELAR), Las Heras 1925, Montevideo 11600, Montevideo, Uruguay. ronellbologna@odon.edu.uy
Key Words Ameloblastoma; B-raf proto-oncogene serine/threonine kinase; B-raf proto-oncogene serine/threonine kinase V600E; Additional mutations; Targeted therapies;
Core Tip Ameloblastoma is a common neoplasia that is developed from odontogenic epithelium. It is an aggressive and recurrent tumor that can present metastases or malignant transformation. This neoplasia is characterized by presenting different clinical and histological varieties as well as several mutations related to its behavior. Nowadays, there are several studies focused on targeted therapies against the mutations of this tumor, one of the most frequent ones being B-raf proto-oncogene serine/threonine kinase (BRAF) V600E, the treatment of which has been associated with good response. These targeted therapies are suitable for resistant tumors. This study focused on BRAF V600E mutations and its additional mutations and targeted therapies.
Citation González-González R, López-Verdín S, Lavalle-Carrasco J, Molina-Frechero N, Isiordia-Espinoza M, Carreón-Burciaga RG, Bologna-Molina R. Current concepts in ameloblastoma-targeted therapies in B-raf proto-oncogene serine/threonine kinase V600E mutation: Systematic review. World J Clin Oncol 2020; 11(1): 31-42
Received
2019-03-23 06:36
Peer-Review Started
2019-03-26 00:40
To Make the First Decision
2019-09-11 00:10
Return for Revision
2019-09-11 09:17
Revised
2019-10-23 19:45
Second Decision
2019-11-05 07:28
Accepted by Journal Editor-in-Chief
Accepted by Company Editor-in-Chief
2019-11-06 19:41
Articles in Press
2019-11-06 19:41
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript
2019-12-18 02:53
ISSN 2218-4333 (online)
Open Access This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Copyright ©The Author(s) 2019. Published by Baishideng Publishing Group Inc. All rights reserved.
Permissions For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website http://www.wjgnet.com